Target Name: CDC45
NCBI ID: G8318
Other Name(s): Cell division cycle 45, transcript variant 2 | Cell division cycle 45 homolog | CDC45 cell division cycle 45 homolog | CDC45 (cell division cycle 45, S.cerevisiae, homolog)-like | CDC45_HUMAN | CDC45L2 | CDC45 variant 2 | CDC45-related protein | Cell division control protein 45 homolog (isoform 2) | Cell division control protein 45 homolog | cell division cycle 45 homolog | cell division cycle 45-like 2 | CDC45 cell division cycle 45-like | Cell division cycle 45-like 2 | Cell division control protein 45 homolog (isoform 3) | human CDC45 | Cell division cycle 45, transcript variant 3 | cell division cycle 45 | MGORS7 | CDC45L | PORC-PI-1 | Human CDC45 | CDC45 variant 3

CDC45: A Potential Drug Target and Biomarker for Cancer Treatment

Cancer is a leading cause of morbidity and mortality worldwide, with over 80% of all deaths due to cancer. The discovery of new treatment options is crucial for improving the treatment outcomes of cancer patients. In recent years, significant advancements have been made in the understanding of the cell division cycle (CDC), which has been identified as a promising target for cancer therapy. One of the key events in the CDC is the transcription factor CDC45, which plays a crucial role in regulating cell division and has been implicated in various cancer-related processes. In this article, we will explore the details of CDC45, its functions, and its potential as a drug target and biomarker for cancer treatment.

Overview of CDC45

CDC45 is a non-coding RNA molecule that belongs to the T-cell factor family 1 (TFF1) and is expressed in various tissues and organs, including brain, heart, and gastrointestinal tract. It is a key regulator of the cell division cycle, responsible for ensuring proper cell proliferation and differentiation. CDC45 functions by binding to specific DNA sequences to regulate the expression of various genes.

In addition to its role in cell division, CDC45 is also involved in various signaling pathways that regulate cell growth, differentiation, and survival. It has been shown to play a crucial role in the regulation of cell cycle progression, and is involved in the development and progression of various types of cancer.

CDC45 as a Drug Target

CDC45's potential as a drug target is due to its unique mechanism of action and its involvement in various signaling pathways. One of the key reasons for its potential as a drug target is its ability to interact with multiple signaling pathways, including the PI3K/Akt signaling pathway, TGF-β signaling pathway, and NF-kappa-B signaling pathway.

The PI3K/Akt signaling pathway is involved in the regulation of cell survival and growth, and is a potential target for cancer therapy. Activation of this pathway by CDC45 has been shown to promote the growth and survival of various cancer cell types. Therefore, inhibitors of PI3K/Akt signaling pathway have been shown to be effective in treating various types of cancer.

The TGF-β signaling pathway is involved in the regulation of cell growth and differentiation, and is also a potential target for cancer therapy. Activation of this pathway by CDC45 has been shown to promote the growth and survival of various cancer cell types. Therefore, inhibitors of TGF-β signaling pathway have also been shown to be effective in treating various types of cancer.

The NF-kappa-B signaling pathway is involved in the regulation of cell inflammation and immune responses, and is a potential target for cancer therapy. Activation of this pathway by CDC45 has been shown to promote the growth and survival of various cancer cell types. Therefore, inhibitors of NF-kappa-B signaling pathway have also been shown to be effective in treating various types of cancer.

In conclusion, CDC45 is a promising drug target due to its involvement in multiple signaling pathways that are involved in cancer development and progression. Further research is needed to fully understand the functions of CDC45 as a drug target and to develop effective treatments for cancer.

CDC45 as a Biomarker

CDC45 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be altered in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that CDC45 has been associated with poor prognosis in patients with various types of cancer. Therefore, measuring the expression of CDC45 may be a useful biomarker for the diagnosis, prognosis, and response to cancer treatment.

In conclusion, CDC45 is a promising biomarker for cancer, as its expression is altered in various types of cancer and it has been associated with poor prognosis in patients with cancer. Further research is needed to fully understand the functions of CDC45 as a biomarker and to develop effective treatments based on its expression.

Protein Name: Cell Division Cycle 45

Functions: Required for initiation of chromosomal DNA replication. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built

More Common Targets

CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF